Group 1 - The company announced a commercialization service agreement with Haisen Bio, effective December 11, 2025, allowing the company to provide CSO services in China [1] - The board believes that this agreement will create synergies in regions and customer groups not fully covered by Haisen Bio, enhance product lifecycle management, and generate recurring service fee income from CSO services [1] - The company expects to leverage its existing infrastructure, sales team, and key customer relationships to create incremental sales and improve the scale, experience, and efficiency of its commercial organization [1] Group 2 - The company has also entered into an exclusive licensing agreement with Haisen Bio, granting limited rights to develop, commercialize, and sell licensed compounds and products in the specified region [1] - Mr. Sun Xin has been appointed as a non-executive director, effective December 11, 2025 [2]
云顶新耀与海森生物订立商业化服务协议及授权许可协议